Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 13/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.41 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20535972 | 1.00 | HTR2A (0.41) | HTR2ASLC6A4KCNH2P2RY1SCN9A | |
| SCHEMBL23709904 | 0.89 | RHEB (0.35) | SCN9ACYP3A4CYP2D6CYP2C19 | |
| SCHEMBL23709945 | 0.88 | LMNA (0.41) | HTR2ASLC6A4KCNH2CYP3A4CYP2C19 | |
| SCHEMBL20536123 | 0.87 | L3MBTL1 (0.39) | P2RY1CYP3A4CYP2C19 | |
| SCHEMBL20536125 | 0.87 | L3MBTL1 (0.39) | P2RY1CYP3A4CYP2C19 | |
| SCHEMBL24113456 | 0.84 | MAPT (0.38) | — | |
| SCHEMBL30009048 | 0.84 | MAPT (0.38) | — | |
| SCHEMBL23702418 | 0.84 | RHEB (0.44) | HTR2ASLC6A4KCNH2SCN9ACHEK2 | |
| SCHEMBL23702419 | 0.84 | RHEB (0.44) | HTR2ASLC6A4KCNH2SCN9ACHEK2 | |
| SCHEMBL18990257 | 0.82 | POLB (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| WO-2018191146-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | RHEB, KRAS, NRAS | HTR2A 4448/4885SLC6A4 4819/4885KCNH2 4734/4885 |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | RHEB, GDI2, KRAS | HTR2A 4490/4885SLC6A4 4806/4885KCNH2 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.